Prognosis by patient risk group with interferon-α (IFN-α) plus daily low-dose cytarabine therapy.
| . | . | . | % Cytogenetic Response . | ||
|---|---|---|---|---|---|
| Risk Group . | No. . | % CHR . | Any . | Major . | CR . |
| Good | 61 | 95 | 82 | 61 | 43 |
| Intermediate | 37 | 95 | 73 | 49 | 24 |
| Poor | 17 | 82 | 53 | 29 | 18 |
| P value | .17 | .05 | .045 | .06 | |
| Abbreviations: CHR, complete hematologic response | |||||
| . | . | . | % Cytogenetic Response . | ||
|---|---|---|---|---|---|
| Risk Group . | No. . | % CHR . | Any . | Major . | CR . |
| Good | 61 | 95 | 82 | 61 | 43 |
| Intermediate | 37 | 95 | 73 | 49 | 24 |
| Poor | 17 | 82 | 53 | 29 | 18 |
| P value | .17 | .05 | .045 | .06 | |
| Abbreviations: CHR, complete hematologic response | |||||